Eye Spectropolarimetry for Neurodegenerative Disease Markers
Summary
USPTO published RETISPEC Inc.'s patent application US20260090709A1 for systems and methods evaluating eye spectropolarimetric data to identify markers of neurodegenerative diseases affecting the central nervous system. The filing (application 19214892) covers imaging analysis using spatial, spectral, and polarimetric data to classify patients into disease status categories. The application was filed May 21, 2025.
What changed
USPTO published RETISPEC Inc.'s patent application US20260090709A1 for evaluating spectropolarimetric data packages of an eye for disease markers. The patent covers systems and methods that analyze imaging data including spatial, spectral, and polarimetric information to classify patients into categories indicating status with respect to neurodegenerative diseases affecting the central nervous system. The application (No. 19214892) names inventors Eliav Shaked, Alon Hazan, Tommaso Alterini, and Joni Petteri Teikari.
Patent applications do not create compliance obligations for third parties. Companies developing eye imaging diagnostics for neurodegenerative disease detection should review the published claims to assess potential freedom-to-operate considerations. Medical device manufacturers in the diagnostic imaging space may wish to monitor this application's prosecution status for competitive intelligence purposes.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
EVALUATING SPECTROPOLARIMETRIC DATA PACKAGES OF AN EYE FOR MARKERS OF DISEASE
Application US20260090709A1 Kind: A1 Apr 02, 2026
Assignee
RETISPEC INC.
Inventors
Eliav Shaked, Alon Hazan, Tommaso Alterini, Joni Petteri Teikari
Abstract
The disclosure relates to systems and methods for evaluating markers of disease by using optical techniques A method includes analyzing data from an imaging of an eye of a patient with at least one processor, the data from the imaging including a plurality of pixels and including, for each pixel, spatial, spectral, and polarimetric data generated from the imaging of the eye. The method further includes based on the analyzing, classifying the patient into at least one category of a plurality of categories, each category of the plurality of categories indicating a status with respect to a neurodegenerative disease that affects a central nervous system. The method further includes generating an output of one or more of the at least one category indicating the status of the patient with respect to the neurodegenerative disease that affects a central nervous system.
CPC Classifications
A61B 3/0025 A61B 3/1225 A61B 5/004 A61B 5/0075 A61B 5/4088 A61B 5/4842 A61B 5/4848 A61B 5/7264 G06T 7/0012 G06T 7/11 G16H 50/20 G16H 50/30 G16H 50/70 A61B 2576/02 G06T 2207/10101 G06T 2207/20081 G06T 2207/20084 G06T 2207/30041 G06T 2207/30168 G06T 2207/30204 G06V 10/267 G06V 10/764 G06V 10/766 G06V 10/82 G06V 2201/03
Filing Date
2025-05-21
Application No.
19214892
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Diagnosis & Surgery (A61B)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Diagnosis & Surgery (A61B) publishes new changes.